Press release


02/08/2017
SOM Biotech licenses its first product and expands to the United States
SOM Biotech
SOM Biotech has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). The geographic expansion, and the clinical development of SOM’s most advanced assets, will be capitalized through the licensing revenues from SOM0226, as well as the commencing Series A fundraising.
 
 
Documentación:
 
 
 
Permalink  
 
Developed by Web4Bio